Evidence map›Paper›PMID 21121053›Full record

Trial reportPacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2011

Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.

Benjamin J Grady, Eric S Torstenson, Paul J McLaren, Paul I W DE Bakker, David W Haas, Gregory K Robbins, Roy M Gulick, Richard Haubrich, Heather Ribaudo, Marylyn D Ritchie

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2016
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Chapter 11: Genome-wide association studies.PLoS computational biology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Benjamin J GradyCenter for Human Genetics Research, Vanderbilt University, Nashville, TN 37232, USA.
Eric S Torstenson
Paul J McLaren
Paul I W DE Bakker
David W Haas
Gregory K Robbins
Roy M Gulick
Richard Haubrich
Heather Ribaudo
Marylyn D Ritchie
Center for Human Genetics · USHarvard University · USBroad Institute · USCornell University · USHarvard University Press · USUniversity of California, San Diego · USVanderbilt University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Colleen F Kelley · 2012 to 2026
$46.0M
NCRR NIH HHS M01 RR000095NCRR NIH HHS RR000095NCRR NIH HHS RR024996NCRR NIH HHS UL1 RR024996NHGRI NIH HHS HG004798NHGRI NIH HHS U01 HG004798NHLBI NIH HHS HL065962NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U19 HL065962NIAID NIH HHS AI062435NIAID NIH HHS AI069439NIAID NIH HHS AI069472NIAID NIH HHS AI077505NIAID NIH HHS AI25859NIAID NIH HHS AI25868NIAID NIH HHS AI25897NIAID NIH HHS AI25903NIAID NIH HHS AI25915NIAID NIH HHS AI27658NIAID NIH HHS AI27660NIAID NIH HHS AI27661NIAID NIH HHS AI27663NIAID NIH HHS AI27664NIAID NIH HHS AI27666NIAID NIH HHS AI32782NIAID NIH HHS AI32783NIAID NIH HHS AI34835NIAID NIH HHS AI34853NIAID NIH HHS AI36214NIAID NIH HHS AI38844NIAID NIH HHS AI38855NIAID NIH HHS AI38858NIAID NIH HHS AI38858-09S1NIAID NIH HHS AI46339NIAID NIH HHS AI46370NIAID NIH HHS AI46376NIAID NIH HHS AI46381NIAID NIH HHS AI46383NIAID NIH HHS AI46386NIAID NIH HHS AI51966NIAID NIH HHS AI54999NIAID NIH HHS AI64086NIAID NIH HHS AI68634NIAID NIH HHS AI68636NIAID NIH HHS AI69415NIAID NIH HHS AI69418NIAID NIH HHS AI69419NIAID NIH HHS AI69423NIAID NIH HHS AI69424NIAID NIH HHS AI69426NIAID NIH HHS AI69428NIAID NIH HHS AI69432NIAID NIH HHS AI69434NIAID NIH HHS AI69439NIAID NIH HHS AI69447NIAID NIH HHS AI69450NIAID NIH HHS AI69452NIAID NIH HHS AI69465NIAID NIH HHS AI69467NIAID NIH HHS AI69470NIAID NIH HHS AI69471NIAID NIH HHS AI69472NIAID NIH HHS AI69474NIAID NIH HHS AI69477NIAID NIH HHS AI69484NIAID NIH HHS AI69494NIAID NIH HHS AI69495NIAID NIH HHS AI69501NIAID NIH HHS AI69502NIAID NIH HHS AI69503NIAID NIH HHS AI69511NIAID NIH HHS AI69513NIAID NIH HHS AI69532NIAID NIH HHS AI69556NIAID NIH HHS K01 AI062435NIAID NIH HHS K24 AI051966NIAID NIH HHS K24 AI064086NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI054999NIAID NIH HHS R01 AI077505NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI025897NIAID NIH HHS U01 AI025903NIAID NIH HHS U01 AI025915NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027660NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI027663NIAID NIH HHS U01 AI027664NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI032783NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046339NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI046376NIAID NIH HHS U01 AI046381NIAID NIH HHS U01 AI046383NIAID NIH HHS U01 AI046386NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069415NIAID NIH HHS U01 AI069418NIAID NIH HHS U01 AI069419NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069426NIAID NIH HHS U01 AI069428NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069439NIAID NIH HHS U01 AI069447NIAID NIH HHS U01 AI069450NIAID NIH HHS U01 AI069452NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069467NIAID NIH HHS U01 AI069470NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069477NIAID NIH HHS U01 AI069484NIAID NIH HHS U01 AI069494NIAID NIH HHS U01 AI069495NIAID NIH HHS U01 AI069501NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI069503NIAID NIH HHS U01 AI069511NIAID NIH HHS U01 AI069513NIAID NIH HHS U01 AI069532NIAID NIH HHS U01 AI069556NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069418NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069426NIAID NIH HHS UM1 AI069428NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069434NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069447NIAID NIH HHS UM1 AI069450NIAID NIH HHS UM1 AI069452NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069467NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069472NIAID NIH HHS UM1 AI069474NIAID NIH HHS UM1 AI069477NIAID NIH HHS UM1 AI069484NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI069495NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI069502NIAID NIH HHS UM1 AI069503NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI069513NIAID NIH HHS UM1 AI069532NIAID NIH HHS UM1 AI069556NIGMS NIH HHS GM080178NIGMS NIH HHS T32 GM080178NLM NIH HHS LM010040NLM NIH HHS R01 LM010040
6 · The paper itself

Abstract

Personalized medicine is a high priority for the future of health care. The idea of tailoring an individual's wellness plan to their unique genetic code is one which we hope to realize through the use of pharmacogenomics. There have been examples of tremendous success in pharmacogenomic associations however there are many such examples in which only a small proportion of trait variance has been explained by the genetic variation. Although the increased use of GWAS could help explain more of this variation, it is likely that a significant proportion of the genetic architecture of these pharmacogenomic traits are due to complex genetic effects such as epistasis, also known as gene-gene interactions, as well as gene-drug interactions. In this study, we utilize the Biofilter software package to look for candidate epistasis contributing to risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens in treatment-naïve participants of AIDS Clinical Trials Group (ACTG) randomized clinical trials. A total of 904 individuals from three ACTG trials with data on efavirenz treatment are analyzed after race-stratification into white, black, and Hispanic ethnic groups. Biofilter was run considering 245 candidate ADME (absorption, distribution, metabolism, and excretion) genes and using database knowledge of gene and protein interaction networks to produce approximately 2 million SNP-SNP interaction models within each ethnic group. These models were evaluated within the PLATO software package using pair wise logistic regression models. Although no interaction model remained significant after correction for multiple comparisons, an interaction between SNPs in the TAP1 and ABCC9 genes was one of the top models before correction. The TAP1 protein is responsible for intracellular transport of antigen to MHC class I molecules, while ABCC9 codes for a transporter which is part of the subfamily of ABC transporters associated with multi-drug resistance. This study demonstrates the utility of the Biofilter method to prioritize the search for gene-gene interactions in large-scale genomic datasets, although replication in a larger cohort is required to confirm the validity of this particular TAP1-ABCC9 finding.

Indexed as

Epistasis, GeneticAlkynesAnti-HIV AgentsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2BenzoxazinesComputational BiologyCyclopropanesDouble-Blind MethodDrug Resistance, ViralGenome-Wide Association StudyHIV-1HIV InfectionsHumansPolymorphism, Single NucleotidePotassium Channels, Inwardly RectifyingABCC9 protein, humanAlkynesAnti-HIV AgentsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2BenzoxazinesCyclopropanesefavirenzPotassium Channels, Inwardly RectifyingReceptors, DrugSulfonylurea ReceptorsTAP1 protein, human

Identifiers

PMID21121053
PMCPMC3094912
OpenAlexW1585965485

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.